"With Today’s Decision, the Commission Contributes to Keeping Drugs Affordable, Preserving Choice of Treatment and Fostering Innovation, to the Benefit of EU Patients and National Healthcare Systems," She Added.Brussels, Oct 31 (Reuters) - The European Commission Has Fined Teva Teva.ta, the World's Largest Generic Drugmaker, 462.6 Million Euros ($503 Million) for Abusing Its Dominant Position to Delay Competition to Its Blockbuster Multiple Sclerosis Medicine Copaxone, Confirming a Reuters Exclusive.
布魯塞爾，10月31日（路透社） - 歐洲委員會對長益處以罰款 長益.長益全球最大的仿製藥生產商，因濫用其主導地位延緩其多發性硬化藥物科帕克松的競爭，被罰款46260萬歐元（50300萬美元） 證實路透社的獨家報道.
The European Commission Said on Thursday It Had Found That Teva Artificially Extended the Patent Protection of Copaxone and Systematically Spread Misleading Information About a Rival Product.
歐洲委員會週四表示，他們發現長益人爲延長了科帕克松的專利保護期，並系統地散佈有關競爭對手產品的誤導信息。
"Today's Decision to Impose an Antitrust Fine on Teva for Disparagement and Misuse of the Patent System Reaffirms the
“今天對長益進行反壟斷罰款和濫用專利制度的決定再次確認了
Commission's Commitment to Competition Enforcement in the Pharmaceutical Sector," Said EU Antitrust Chief Margrethe Vestager.
歐盟反壟斷首席執行官瑪格麗特·維斯塔格表示，委員會致力於在藥品板塊進行競爭執法。
"With Today’s Decision, the Commission Contributes to Keeping Drugs Affordable, Preserving Choice of Treatment and Fostering Innovation, to the Benefit of EU Patients and National Healthcare Systems," She Added.
她補充說：「通過今天的決定，委員會有助於確保藥品價格合理，保留治療選擇，並促進創新，使歐盟患者和國民衛生系統受益。」
($1 = 0.9197 Euros)
（1美元=0.9197歐元）
(Reporting by Sudip Kar-Gupta;
Editing by Tassilo Hummel/Foo Yun Chee)
（報道：Sudip Kar-Gupta；
編輯：Tassilo Hummel/Foo Yun Chee）
